500
Participants
Start Date
March 16, 2021
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
NYU Langone Health, New York
Northwell Health - Lenox Hill Hospital, New York
Carnegie Mellon University, Allegheny Health Network, Allegheny General Hospital, Pittsburgh
Johns Hopkins University, Baltimore
Virginia Commonwealth University, Richmond
Cleveland Clinic, Cleveland
The Linder Research Center at The Christ Hospital, Cincinnati
Detroit Medical Center, Detroit
Midwest Cardiovascular Research Foundation, Davenport
Minneapolis Heart Institute Foundation, Minneapolis
Mayo Clinic - PPDS, Rochester
Northwestern University, Chicago
Barnes-Jewish Hospital/Washington University, St Louis
University of Nebraska, Omaha
University of Texas Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
University of Utah, Salt Lake City
Pima Heart and Vascular, Tucson
Cedars-Sinai Medical Center, Los Angeles
Scripps Health, San Diego
University of California San Diego Medical Center, La Jolla
Legacy Medical Group, Cardiology, Portland
Seattle Children's Hospital, Seattle
Swedish Medical Center - Cherry Hill, Seattle
Alaska Heart & Vascular Institute, Anchorage
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
TKL Research Inc., Fair Lawn
University of Vermont Medical Center, Burlington
Lead Sponsor
Collaborators (1)
Kiniksa Pharmaceuticals (UK), Ltd.
INDUSTRY
Kiniksa Pharmaceuticals International, plc
INDUSTRY